The competition among the players operating in the global antibacterial drugs market is likely to intensify as they strive to develop differentiated and innovative products, states Transparency Market Research (TMR) in a research report. The market is fragmented in nature due to the presence of numerous companies. The three key players in the market, Pfizer Inc., Merck & Co. Inc., and GlaxoSmithKline plc, collectively accounted for a share of 45.2% in 2014 in the global antibacterial drugs market.
According to a TMR analyst, “To gain a prominent and stable position in the market, companies are entering into strategic agreements, mergers and acquisitions, business expansions, and product innovation.” For instance, Forest Laboratories was acquired by Allergen plc in July 2014 to gain market rights and develop advanced products to treat patients with disorders related to the respiratory system, anti-infection, gastrointestinal, cardiovascular system, and the central nervous system.
The global antibacterial drugs market is projected to decline at a -1.3% CAGR from 2015 to 2023. In 2014, the market was worth US$43.9 bn but is likely to fall to a valuation of US$38.8 bn by the end of 2023.
Request a PDF Brochure with Report Analysis:
β -lactams to Retain Popularity until 2023
Based on class, β-lactams dominated the global antibacterial drugs market with a valuation of US$25.1 bn in 2015 and is likely to stand at US$24.2 bn by 2023. β-lactams are antibacterial drugs that possess inhibition characteristics and have a common β-lactam ring in their formulation. The growing demand for this antibacterial drug can be attributed to the rising frequency of infectious diseases such as MRSA, tuberculosis, pneumonia, and clostridium difficile. Factors such as the burgeoning demand for efficient and inexpensive treatment for bacterial infections, a rising geriatric population, and increasing multi-drug resistant bacterial strains are further expected to push the growth of the global market for antibacterial drugs.
β-lactams are expected to be trailed with a huge gap by quinolones until 2023. The market for quinolones is projected to be worth US$6.0 bn in 2023. The sales of this class of drug are expected to be steady owing to the protection it provides against bacterial infections in the urinary tract, stomach, lungs, sinuses, and skin.
Geographically, the global antibacterial drugs market is segmented into North America, Asia Pacific, Europe, Latin America, and the Rest of the World. Asia Pacific dominated the market in 2014 both in terms of revenue share and growth. The market for antibacterial drugs in Asia Pacific stood at US$19.2 bn in 2015 and is likely to rise to US$19.7 bn in 2023.
The Asia Pacific market for antibacterial drugs is the only market to exhibit a positive CAGR over the forecast period. This growth can be significantly attributed to the well-developed pharmaceutical and extensive economic growth in countries such as Japan, China, India, Thailand, Taiwan, South Korea, Singapore, Indonesia, New Zealand, and Australia.
Alarming Rise in Incidence of Infectious Diseases to Drive Mass Adoption
Every year billions of people are affected by pathogenic bacteria, which lead to various infectious diseases. The most common infectious diseases caused by these type of bacteria are urinary tract infections, impetigo, and pneumonia. According to a World Health Organization report, each year almost 1.1 million children under the age of five die of pneumonia. To combat these serious problems, governments across the world are taking initiatives to spread awareness about antibacterial drugs and increase its consumption across urban and rural areas. Governments are also funding and investing in research and development projects to develop advanced and more effective antibacterial drugs. However, this market is expected to face challenges from the upcoming expiration of old patents and subsequent launch of substitutes and generic drugs.
This review is based on a Transparency Market Research report titled, “Antibacterial Drugs Market (Drug Class – Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/Fluoroquinolones, Macrolides, Phenicols, and Miscellaneous Antibacterials; Pipeline – Actoxumab/Aezlotoxumab, (MK-3415A), Surotomycin (MK-4261), Arikace, Cadazolid, Ciprofloxacin/Fluocinolone Acetonide, Zempia (E-101), Carbavance (meropenem/RPX7009), Ozenoxacin, RHB-105, SPL7013, Delafloxacin, Solithromycin (CEM-101), Eravacycline, Delamanid, SYM-1219, Omadacycline (PTK-0796), and Plazomycin) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”
Browse Full Research Report on Antibacterial Drugs Market:
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Browse market research blog: